- Home
- IOVA vs MHN Comparison
IOVA vs MHN Comparison
Compare IOVA & MHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IOVA | MHN |
|---|---|---|
| Founded | 2007 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 968.6M | 293.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IOVA | MHN |
|---|---|---|
| Price | $2.21 | $10.30 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $10.36 | N/A |
| AVG Volume (30 Days) | ★ 9.8M | 59.2K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.17% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $250,425,000.00 | N/A |
| Revenue This Year | $60.94 | N/A |
| Revenue Next Year | $60.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 175.62 | N/A |
| 52 Week Low | $1.64 | $8.69 |
| 52 Week High | $8.56 | $10.81 |
Technical Indicators
Market Signals| Indicator | IOVA | MHN |
|---|---|---|
| Relative Strength Index (RSI) | 46.56 | 47.37 |
| Support Level | $2.18 | $10.25 |
| Resistance Level | $2.32 | $10.39 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 18.11 | 21.82 |
Price Performance
Historical ComparisonAbout IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About MHN Blackrock MuniHoldings New York Quality Fund Inc.
BLACKROCK MUNIHOLDINGS NEW YORK QUALITY FUND, INC. is a closed-ended management investment company. The fund's investment objective is to provide shareholders with current income exempt from federal income tax and New York State and New York City personal income taxes.